Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

8月4日，沃森生物（300142）公告称，由公司、复旦大学、上海蓝鹊生物医药有限公司及公司子公司玉溪沃森生物技术有限公司、北京沃森创新生物技术有限公司联合研发的呼吸道合胞病毒mRNA疫苗向国家药品监督管理局申请临床试验，并于近日获得《受理通知书》。

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

8月3日晚间沃森生物 (300142)公告，公司与复旦大学、上海蓝鹊生物医药有限公司等联合研发的呼吸道合胞病毒mRNA疫苗已向国家药品监督管理局申请临床试验，并于近日获得受理。该疫苗为基于自主研发的“mRNA疫苗技术平台”开发，用于预防呼吸道合胞病毒感染引起的下呼吸道相关疾病。